Literature DB >> 30656697

External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity and Lifestyle study.

Loai Albarqouni1, Jennifer A Doust1, Dianna Magliano2, Elizabeth Lm Barr2,3, Jonathan E Shaw2, Paul P Glasziou1.   

Abstract

OBJECTIVES: To evaluate the performance of the 2013 Pooled Cohort Risk Equation (PCE-ASCVD) for predicting cardiovascular disease (CVD) in an Australian population; to compare this performance with that of three frequently used Framingham-based CVD risk prediction models.
DESIGN: Prospective national population-based cohort study.
SETTING: 42 randomly selected urban and non-urban areas in six Australian states and the Northern Territory. PARTICIPANTS: 5453 adults aged 40-74 years enrolled in the Australian Diabetes, Obesity and Lifestyle study and followed until November 2011. We excluded participants who had CVD at baseline or for whom data required for risk model calculations were missing. MAIN OUTCOME MEASURES: Predicted and observed 10-year CVD risks (adjusted for treatment drop-in); performance (calibration and discrimination) of four CVD risk prediction models: 1991 Framingham, 2008 Framingham, 2008 office-based Framingham, 2013 PCE-ASCVD.
RESULTS: The performance of the 2013 PCE-ASCVD model was slightly better than 1991 Framingham, and each was better the two 2008 Framingham risk models, both in men and women. However, all four models overestimated 10-year CVD risk, particularly for patients in higher deciles of predicted risk. The 2013 PCE-ASCVD (7.5% high risk threshold) identified 46% of men and 18% of women as being at high risk; the 1991 Framingham model (20% threshold) identified 17% of men and 2% of women as being at high risk. Only 16% of men and 11% of women identified as being at high risk by the 2013 PCE-ASCVD experienced a CV event within 10 years.
CONCLUSIONS: The 2013 PCE-ASCVD or 1991 Framingham should be used as CVD risk models in Australian. However, the CVD high risk threshold for initiating CVD primary preventive therapy requires reconsideration.
© 2019 AMPCo Pty Ltd.

Entities:  

Keywords:  Epidemiology

Mesh:

Year:  2019        PMID: 30656697     DOI: 10.5694/mja2.12061

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  5 in total

1.  Development and internal validation of the Edmonton Obesity Staging System-2 Risk screening Tool (EOSS-2 Risk Tool) for weight-related health complications: a case-control study in a representative sample of Australian adults with overweight and obesity.

Authors:  Evan Atlantis; James Rufus John; S L Hocking; Kath Peters; Kathryn Williams; Paul Dugdale; P Fahey
Journal:  BMJ Open       Date:  2022-06-22       Impact factor: 3.006

2.  Absolute cardiovascular risk scores and medication use in rural India: a cross-sectional study.

Authors:  Mulugeta Molla Birhanu; Roger G Evans; Ayse Zengin; Michaela Riddell; Kartik Kalyanram; Kamakshi Kartik; Oduru Suresh; Nihal Jacob Thomas; Velandai K Srikanth; Amanda G Thrift
Journal:  BMJ Open       Date:  2022-04-22       Impact factor: 3.006

3.  Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia.

Authors:  Kaitlyn Hastings; Clara Marquina; Jedidiah Morton; Dina Abushanab; Danielle Berkovic; Stella Talic; Ella Zomer; Danny Liew; Zanfina Ademi
Journal:  Pharmacoeconomics       Date:  2022-01-17       Impact factor: 4.558

4.  External validation and clinical usefulness of three commonly used cardiovascular risk prediction scores in an Emirati population: a retrospective longitudinal cohort study.

Authors:  Saif Al-Shamsi; Romona Devi Govender; Jeffrey King
Journal:  BMJ Open       Date:  2020-10-28       Impact factor: 2.692

5.  Predicting Australian Adults at High Risk of Cardiovascular Disease Mortality Using Standard Risk Factors and Machine Learning.

Authors:  Shelda Sajeev; Stephanie Champion; Alline Beleigoli; Derek Chew; Richard L Reed; Dianna J Magliano; Jonathan E Shaw; Roger L Milne; Sarah Appleton; Tiffany K Gill; Anthony Maeder
Journal:  Int J Environ Res Public Health       Date:  2021-03-19       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.